AMT Nominates Three High Profile Executives to Supervisory Board and Expands Management Team With Director Regulatory Affairs and Senior Clinical Consultant

Joseph Feczko (ex-Pfizer); Steven Holtzman (Infinity Pharmaceuticals); François Meyer (ex-Aventis) Slated to Reinforce Supervisory Board

AMSTERDAM, August 9, 2010 - Amsterdam Molecular Therapeutics (Euronext: AMT), a leader in
the field of human gene therapy, today announced that it has nominated three
international pharmaceutical executives to join the Company's Supervisory
Board of Directors. The Company has issued a notice for an Extraordinary
General Meeting (EGM) of Shareholders on September 20, 2010, for the election
of the nominees. In connection with these proposed appointments, George
Morstyn will step down from the Board.

"We are pleased to nominate three highly experienced
executives from the sector for appointment by AMT's Shareholders to our
Supervisory Board. We are at an important juncture in the development of AMT:
completion of the approval process with the EMA for marketing authorization
of the first gene therapy treatment in the Western world and the pursuit of
several other promising projects. For the next stage of our development we
want to strengthen the Supervisory Board as well as Management. We are
excited that three highly recognized scientists and executives have accepted
to join in AMT's effort," said Ferdinand Verdonck, Chairman of the
Supervisory Board. "George Morstyn will leave the Board to pursue other
activities in his home country. The Board thanks George for his highly
valuable contributions to the Company's development during the past two years
and wishes him all the best in his new endeavors."

"We expect that AMT will derive an enormous benefit from
leveraging the impressive track record of our Board nominees in numerous key
areas such as clinical and product development, regulatory affairs, product
launches, and licensing. We consider their acceptance to join our Board as an
important validation of our platform and our strategic focus on orphan
indications, and look forward to working together with them," said Jörn
Aldag, Chief Executive Officer of AMT.

"In addition, we are happy to announce the appointments of Dr.
Claudia Meyer, who will join the Company as Director Regulatory Affairs, and
Dr. Gerald Haase as a senior clinical consultant," continued Aldag. "Claudia
joins us from Human Genome Sciences where she was responsible for European
regulatory affairs. Prior to that she was responsible for regulatory affairs
worldwide for a part of CSL Behring's product portfolio. Gerald was a Senior
Medical Officer at the UK Medicines and Healthcare products Regulatory Agency
for 13 years. Prior to joining the MHRA, he held several positions as Medical
Director in the pharmaceutical industry in the UK, France and Switzerland,
and from 2005 to 2008 was a clinical consultant with Parexel, one of the
leading global clinical research organizations. Both are joining us just at a
time where their ample regulatory experience is of highest importance for the
Company."

Background on Board nominees

Joseph M. Feczko, M.D.

Joseph Feczko was, until May, 2009, Senior Vice President and
Chief Medical Officer (CMO) of Pfizer, Inc., and a member of the Executive
Leadership Team with global responsibilities for all aspects of the company's
medical, regulatory and safety activities. Following a time in private
practice, he joined Pfizer in 1982 in New York. He then worked for ten years
in the United Kingdom for both Pfizer and Glaxo where his responsibilities
included supervising clinical research, regulatory affairs, data management
and safety reporting. He returned to Pfizer in New York in 1996, where he
held positions of increasing responsibility in clinical research, and
regulatory affairs and safety, culminating in the role of CMO.

Dr. Feczko is currently a member of the Board of Directors of
the Foundation for the National Institutes of Health, Research!America, the
International Longevity Center and the New York Academy of Medicine (all US).

He is a member of the Board of Directors of the Accordia
Global Health Foundation and the Technical Expert Committee for Trachoma on
the International Trachoma Initiative of the Task Force for Global Health. He
is also a member of the Governing Board of the Technology Strategy Board of
the United Kingdom.

He is currently Chairman of the Board of Directors of Cardoz
Pharmaceuticals AB (Sweden), and a member of the Board of Directors of Keryx
Biopharmaceuticals, Inc. (US).

Dr. Feczko is board-certified in Internal Medicine and a
specialist in Infectious Diseases. He has a B.Sc. degree from Loyola
University Chicago, and an M.D. from the University of Illinois College of
Medicine.

Steven H. Holtzman

Steven Holtzman, Executive Chairman of Infinity
Pharmaceuticals, Inc. (US), is a highly experienced biotech entrepreneur, who
has founded and led a number of life sciences companies. He also has
substantial experience in building collaborations with major pharmaceutical
companies and licensing products. From 1996 to 2001, Mr. Holtzman served as a
Presidential Appointee to the United States National Bioethics Advisory
Commission, the principal advisory body to the President and Congress on
ethical issues in the biomedical and life sciences.

Mr. Holtzman served as Chief Executive Officer 2006 to 2009
and President 2007 to 2008 of Infinity Pharmaceuticals. He was also a
co-founder of Infinity Discovery, Inc. and served as its Chief Executive
Officer and as Chair of its Board of Directors from inception in 2001 until
the time of its merger with Infinity Pharmaceuticals' predecessor company in
2006. He also served as President of Infinity Discovery from 2001 to 2006.
From 1994 to 2001, he served as Chief Business Officer of Millennium
Pharmaceuticals, Inc. (US), a publicly traded pharmaceutical company. Prior
to joining Millennium, from 1986 to 1994 Mr. Holtzman was a founder and
Executive Vice President of DNX Corporation, a publicly-traded biotechnology
company.

In addition to his role at Infinity, he is currently a member
of the Board of Directors of Anadys Pharmaceuticals, Inc. (US) and Sartori
Pharmaceuticals, Inc. (US).

Mr. Holtzman graduated from Michigan State University and
received his B.Phil. from Oxford University, which he attended as a Rhodes
Scholar.

François Meyer

François Meyer was General Director for Research and
Development at Aventis Pharma, France until 2002 and subsequently
Director-General of Aventis' Gene Therapy Division, Gencell, until his
retirement in 2006. He joined Gencell as Vice-President in 1996, within the
Rhône-Poulenc Group, prior to the formation of Aventis when Rhone-Poulenc
merged with Hoechst. He was promoted to Vice President of RPR Global Research
in 1997, and Corporate Senior Vice President of Global Research in 1998.

In 1992, Dr. Meyer joined Sandoz Pharma's gene and cell
therapy business as Vice President, while he also served as a member of the
company's Corporate Research Board. From 1989 to 1992, he was Director of
Research at the CNRS. From 1980 - 1984, he built and headed the Molecular
Genetics department in the newly formed Biotechnology division at Ciba-Geigy,
where he was responsible for the discovery and production of new recombinant
proteins.

He is a member of the Board of Directors of BioSeek, Inc.
(US), Introgen Therapeutics, Inc. (US), Gene Therapy, Inc. (US), and Urogene
SA (France), and a member of the Scientific Advisory Boards of Genethon
(France), Systemix, Inc. (US) and Biotransplant, Inc. (US).

Dr. Meyer graduated from the Swiss Federal Institute of
Technology (ETFH), in Zurich, and studied Biochemistry and Molecular Biology
at the University of Zurich. He received his Ph.D. from the Institute for
Molecular Biology in 1978, and became a Senior Member at the Institute.
During his career, Dr. Meyer has also served as a lecturer in Molecular
Biology at the Swiss Federal Institute of Technology.

Details for the Extraordinary General Meeting

AMT's EGM is scheduled for September 20, 2010 at 12.00 noon,
at the Company's offices, Meibergdreef 61, Amsterdam, The Netherlands. The
formal notice of the EGM can be accessed within the investor section at
www.amtbiopharma.com.

About Amsterdam Molecular Therapeutics

AMT, founded in 1998 and based in Amsterdam, is a leader in
the development of human gene based therapies. Using AAV as the delivery
vehicle of choice for therapeutic genes, the company has been able to design
and validate what is probably the first stable and scalable AAV production
platform. This safe and efficacious proprietary platform offers a unique
manufacturing capability which can be applied to a large number of rare
(orphan) diseases that are caused by one faulty gene. Currently, AMT has a
product pipeline with several AAV-based gene therapy products in LPLD,
Hemophilia B, DMD, Acute Intermittent Porphyria and Parkinson's Disease at
different stages of research or development.

Certain statements in this press release are "forward-looking
statements" including those that refer to management's plans and expectations
for future operations, prospects and financial condition. Words such as
"strategy," "expects," "plans," "anticipates," "believes," "will,"
"continues," "estimates," "intends," "projects," "goals," "targets" and other
words of similar meaning are intended to identify such forward-looking
statements. Such statements are based on the current expectations of the
management of Amsterdam Molecular Therapeutics only. Undue reliance should
not be placed on these statements because, by their nature, they are subject
to known and unknown risks and can be affected by factors that are beyond the
control of AMT. Actual results could differ materially from current
expectations due to a number of factors and uncertainties affecting AMT's
business, including, but not limited to, the timely commencement and success
of AMT's clinical trials and research endeavors, delays in receiving U.S.
Food and Drug Administration or other regulatory approvals (i.e. EMA, Health
Canada), market acceptance of AMT's products, effectiveness of AMT's
marketing and sales efforts, development of competing therapies and/or
technologies, the terms of any future strategic alliances, the need for
additional capital, the inability to obtain, or meet, conditions imposed for
required governmental and regulatory approvals and consents. AMT expressly
disclaims any intent or obligation to update these forward-looking statements
except as required by law. For a more detailed description of the risk
factors and uncertainties affecting AMT, refer to the prospectus of AMT's
initial public offering on June 20, 2007, and AMT's public announcements made
from time to time.

For further enquiries: Jörn Aldag, Chief Executive Officer, Tel +31-(0)20-566-7394, Tel +31-(0)6-8195-3060, j.aldag at amtbiopharma.com